Stock Analysis
Bayer (ETR:BAYN) Full Year 2023 Results
Key Financial Results
- Revenue: €47.6b (down 6.1% from FY 2022).
- Net loss: €2.94b (down by 171% from €4.15b profit in FY 2022).
- €2.99 loss per share (down from €4.22 profit in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Bayer Meets Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations.
Looking ahead, revenue is forecast to grow 1.1% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany.
Performance of the German Pharmaceuticals industry.
The company's shares are down 11% from a week ago.
Risk Analysis
It is worth noting though that we have found 2 warning signs for Bayer that you need to take into consideration.
Valuation is complex, but we're helping make it simple.
Find out whether Bayer is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About XTRA:BAYN
Bayer
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide.
Fair value with moderate growth potential.